276 related articles for article (PubMed ID: 33586348)
1. EphA2 promotes tumorigenicity of cervical cancer by up-regulating CDK6.
Huang C; Chen Z; He Y; He Z; Ban Z; Zhu Y; Ding L; Yang C; Jeong JH; Yuan W; Yang L
J Cell Mol Med; 2021 Mar; 25(6):2967-2975. PubMed ID: 33586348
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo.
Liu Y; Yu C; Qiu Y; Huang D; Zhou X; Zhang X; Tian Y
J Cancer Res Clin Oncol; 2012 Feb; 138(2):195-202. PubMed ID: 22086185
[TBL] [Abstract][Full Text] [Related]
3. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas.
Binda E; Visioli A; Giani F; Lamorte G; Copetti M; Pitter KL; Huse JT; Cajola L; Zanetti N; DiMeco F; De Filippis L; Mangiola A; Maira G; Anile C; De Bonis P; Reynolds BA; Pasquale EB; Vescovi AL
Cancer Cell; 2012 Dec; 22(6):765-80. PubMed ID: 23238013
[TBL] [Abstract][Full Text] [Related]
4. EphA2 as a promoter of melanoma tumorigenicity.
Margaryan NV; Strizzi L; Abbott DE; Seftor EA; Rao MS; Hendrix MJ; Hess AR
Cancer Biol Ther; 2009 Feb; 8(3):279-88. PubMed ID: 19223760
[TBL] [Abstract][Full Text] [Related]
5. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.
Yu L; Chen D; Song J
Thorac Cancer; 2020 Mar; 11(3):603-611. PubMed ID: 31953899
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-26b Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells by Targeting EphA2.
Jin Q; Li XJ; Cao PG
Tohoku J Exp Med; 2016 Feb; 238(2):143-51. PubMed ID: 26843134
[TBL] [Abstract][Full Text] [Related]
7. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
Zhou Y; Sakurai H
Biol Pharm Bull; 2017; 40(10):1616-1624. PubMed ID: 28966234
[TBL] [Abstract][Full Text] [Related]
8. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.
Mao L; Yuan W; Cai K; Lai C; Huang C; Xu Y; Zhong S; Yang C; Wang R; Zeng P; Huang H; Chen Z; Chen Z
Oncogene; 2021 May; 40(20):3610-3623. PubMed ID: 33941853
[TBL] [Abstract][Full Text] [Related]
9. BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways.
Li Y; Cui N; Zheng PS; Yang WT
Oncotarget; 2017 Jul; 8(30):49238-49252. PubMed ID: 28514765
[TBL] [Abstract][Full Text] [Related]
10. CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
Yang B; Chen J; Teng Y
J Immunol Res; 2021; 2021():6645885. PubMed ID: 33628849
[TBL] [Abstract][Full Text] [Related]
11. EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells.
Huang J; Xiao D; Li G; Ma J; Chen P; Yuan W; Hou F; Ge J; Zhong M; Tang Y; Xia X; Chen Z
Oncogene; 2014 May; 33(21):2737-47. PubMed ID: 23752181
[TBL] [Abstract][Full Text] [Related]
12. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.
Guo H; Miao H; Gerber L; Singh J; Denning MF; Gilliam AC; Wang B
Cancer Res; 2006 Jul; 66(14):7050-8. PubMed ID: 16849550
[TBL] [Abstract][Full Text] [Related]
13. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties.
Li JY; Xiao T; Yi HM; Yi H; Feng J; Zhu JF; Huang W; Lu SS; Zhou YH; Li XH; Xiao ZQ
Cancer Lett; 2019 Mar; 444():162-174. PubMed ID: 30583071
[TBL] [Abstract][Full Text] [Related]
14. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
[TBL] [Abstract][Full Text] [Related]
15. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo.
Yuan W; Chen Z; Chen Z; Wu S; Guo J; Ge J; Yang P; Huang J
Neoplasma; 2012; 59(1):105-13. PubMed ID: 22103904
[TBL] [Abstract][Full Text] [Related]
16. DUSP7 inhibits cervical cancer progression by inactivating the RAS pathway.
Bai H; Song M; Jiao R; Li W; Zhao J; Xiao M; Jin M; Zhang Z; Deng H
J Cell Mol Med; 2021 Oct; 25(19):9306-9318. PubMed ID: 34435746
[TBL] [Abstract][Full Text] [Related]
17. MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2.
Li H; Sun Q; Han B; Yu X; Hu B; Hu S
Int J Clin Exp Pathol; 2015; 8(5):4782-90. PubMed ID: 26191168
[TBL] [Abstract][Full Text] [Related]
18. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Fukuchi M; Nakajima M; Kuwano H
Int J Cancer; 2003 Feb; 103(5):657-63. PubMed ID: 12494475
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer.
Kapora E; Feng S; Liu W; Sakhautdinova I; Gao B; Tan W
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31266812
[TBL] [Abstract][Full Text] [Related]
20. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
Li R; Liu GZ; Luo SY; Chen R; Zhang JX
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
